Symoens J
Janssen Pharmaceutica, Beerse, Belgium.
Proc R Soc Med. 1977;70 Suppl 1(Suppl 1):4-8. doi: 10.1177/00359157770700S103.
Intravenous treatment with miconazole brought about the recovery of 90% of patients with gastrointestinal or systemic candidosis. Miconazole given by the same route has also been found effective in the treatment of cryptococcosis, coccidioidomycosis, and paracoccidioidomycosis. Cryptococcal and coccidioidal meningitis have been cured by combined intravenous and intrathecal instillation, although treatment of aspergillosis has presented difficulty. Oral treatment was effective in curing dermatophyte skin infections and systemic mycoses caused by sensitive organisms such as paracoccidioides, blastomyces and histoplasma. The question of blood levels following oral and intravenous administration is discussed. Side effects of the drug were few, and included chills, dizziness, skin rash, itching and diarrhoea. Thus miconazole can safely be given to seriously ill patients. Its behaviour in the body is not influenced by renal insufficiency and no drug induced resistance has been reported.
静脉注射咪康唑可使90%的胃肠道或全身性念珠菌病患者康复。经相同途径给药的咪康唑在治疗隐球菌病、球孢子菌病和副球孢子菌病方面也已被证明有效。尽管治疗曲霉菌病存在困难，但联合静脉注射和鞘内注射已治愈了隐球菌性和球孢子菌性脑膜炎。口服治疗对治愈由敏感生物体如副球孢子菌、芽生菌和组织胞浆菌引起的皮肤癣菌皮肤感染和全身性真菌病有效。文中讨论了口服和静脉给药后的血药浓度问题。该药物的副作用较少，包括寒战、头晕、皮疹、瘙痒和腹泻。因此，咪康唑可安全地用于重症患者。其在体内的行为不受肾功能不全的影响，也未报告有药物诱导的耐药性。
